Neonatal-onset multisystem inflammatory disease caused by a de novo NLRP3 gene mutation: a case report and literature review

Background: Neonatal-onset multisystem inflammatory disease (NOMID) is a rare autoinflammatory disease caused by NLRP3 mutations, leading to excessive interleukin-1β activation and potential irreversible organ damage.

Case description: We report a female neonate presenting at birth with urticaria-like rash, intermittent fever, aseptic meningitis, lymphadenopathy, and polyarthritis with persistently elevated inflammatory markers. Whole-exome sequencing revealed a heterozygous de novo NLRP3 mutation (c.2263G>A, p.Gly755Arg), confirmed as pathogenic. Conventional therapies, including antibiotics, corticosteroids, and antihistamines, failed to achieve symptom control. Canakinumab (2–3 mg/kg per 8 weeks) was initiated, leading to rapid resolution of fever, rash, and inflammatory markers, and successful induction of clinical and biochemical remission with canakinumab during the 13-month follow-up.

Conclusion: This case highlights the importance of early recognition of NOMID in neonates with antibiotic-unresponsive systemic inflammation. Early genetic confirmation and targeted IL-1 blockade with canakinumab are crucial to preventing devastating complications.

1 Introduction

Neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurologic, cutaneous, and articular (CINCA) syndrome, represents the most severe clinical phenotype within the spectrum of cryopyrin-associated periodic syndromes (CAPS) (1). This monogenic autoinflammatory disease is caused by gain-of-function mutations in the NLRP3 gene, which encodes cryopyrin, a critical component of the inflammasome complex (1). These mutations lead to constitutive overproduction of interleukin-1β (IL-1β), driving uncontrolled systemic inflammation (2). Recent structural studies using cryo-EM have elucidated the mechanisms of NLRP3 inflammasome activation and inhibition, providing insights into disease pathogenesis (3).

The classic clinical triad of NOMID includes a chronic urticarial-like rash, central nervous system (CNS) involvement (typically chronic aseptic meningitis), and arthropathy, frequently accompanied by characteristic facial dysmorphism such as frontal bossing (4). The disease follows a relentlessly progressive course; without appropriate treatment, it leads to devastating complications including intellectual disability, sensorineural hearing loss, visual impairment, and secondary amyloidosis (1). Data from global registries, such as the Eurofever Registry, highlight that CNS and articular manifestations are predominant in NOMID, with significant heterogeneity in clinical presentation (5).

NOMID is exceedingly rare worldwide, with approximately 100 cases reported since its initial description (5). In China, several cases have been reported, but a comprehensive analysis of the clinical and genetic spectrum is lacking (6–21). Despite its distinctive features, diagnosis is frequently delayed by years due to its rarity and the nonspecific nature of its early symptoms, which often mimic neonatal sepsis or other inflammatory conditions (15). This diagnostic delay contributes significantly to the accumulation of irreversible organ damage. Recent studies from Japan and Europe emphasize the importance of early genetic testing to confirm NLRP3 mutations, including somatic mosaicism, which may account for some atypical cases (22, 23).

The management of NOMID has been revolutionized by the advent of IL-1 targeted therapies. Biologic agents such as anakinra (24, 25) and canakinumab (26) have demonstrated remarkable efficacy in achieving rapid control of inflammation and halting disease progression. Long-term follow-up studies from large international cohorts, including the Eurofever Registry (27) and a nationwide Japanese survey (28) confirm that canakinumab provides sustained disease remission with a favorable safety profile. Supported by robust evidence, the 2021 EULAR/ACR points to consider endorse IL-1 inhibition as a first-line treatment for IL-1-mediated autoinflammatory diseases (29).

Here, we present a seminal case of NOMID in a Chinese neonate, representing the earliest genetically confirmed diagnosis and successful treatment initiation in China. The patient harbored a de novo NLRP3 mutation (p.Gly755Arg) and was treated with canakinumab from 48 days of age, resulting in rapid biochemical and clinical remission. Furthermore, we provide a comprehensive systematic review and analysis of all reported Chinese NOMID cases, aiming to delineate the clinical and genetic spectrum of this disease in China and to highlight the critical importance of early recognition and intervention in the neonatal period.

2 Materials and methods

2.1 Case report

Clinical, laboratory, imaging, and genetic data were comprehensively collected from the electronic medical record system of Wuhan Children's Hospital. The diagnosis of NOMID was confirmed based on characteristic clinical features and genetic findings. Informed written consent was obtained from the parents for the publication of this case report and any accompanying images. The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (Ethics Committee) of Wuhan Children's Hospital (Approval No: 2025R085-E01).

2.2 Literature review and data analysis

To comprehensively summarize the clinical characteristics of Chinese patients with NOMID, we conducted a structured literature review. The literature search was conducted up to August 2025, covering Chinese databases (China National Knowledge Infrastructure-CNKI, WanFang Data) and English databases (PubMed, Embase), with the search timeframe spanning from the inception of each database to August 2025. The search strategy employed a combination of Medical Subject Headings (MeSH) terms and keywords, including: (“NOMID” OR “CINCA” OR “Chronic Infantile Neurological Cutaneous Articular Syndrome” OR “neonatal-onset multisystem inflammatory disease” OR “NLRP3” OR “CIAS1”) AND (“China” OR “Chinese”). The search was restricted to articles published in Chinese and English, with the age restricted to the range of 0–18 years. The literature search and selection process followed the PRISMA 2020 guidelines (30). As shown in Figure 1, our search identified 161 records from PubMed and Chinese databases. After screening titles and abstracts, 144 records were excluded as irrelevant to CINCA/NOMID. The remaining 16 articles underwent full-text review, all of which met the inclusion criteria and were included in the systematic review.

Figure 1

Figure 1. PRISMA 2020 flow diagram. Adapted from: Page et al. (30).

All case reports and case series describing patients of Chinese ethnicity with a clinical and/or genetic diagnosis of NOMID/CINCA were included. Data extraction was performed using a standardized form. The extracted information included: (1) demographic data (gender, current age, age of onset, age at diagnosis); (2) clinical manifestations (rash, fever, CNS involvement, musculoskeletal symptoms, organomegaly, etc.); (3) laboratory and imaging findings; (4) genetic results. Data were summarized descriptively and are presented in Supplementary Table S1.

2.3 Risk of bias assessment

Given that all studies included in this systematic review are case reports or small case series, a formal risk of bias assessment using tools designed for controlled trials (e.g., the Cochrane Risk of Bias tool) was not applicable. The inherent limitations of case reports, including their retrospective nature, potential for selection bias, and inconsistent reporting of outcomes, are acknowledged. To ensure data quality and reliability, we evaluated each included case based on the completeness of reporting across four key domains: (1) patient demographics, (2) clinical manifestations, (3) genetic confirmation of the NLRP3 mutation, and (4) treatment regimen and response. Cases with critically missing information in these domains were excluded during the screening phase.

3 Case presentation

A female infant was born at 37⁺⁶ weeks gestation via spontaneous vaginal delivery through grade III meconium-stained amniotic fluid. The pregnancy was otherwise uncomplicated. Birth weight was 2,700 g (25th percentile). The parents were non-consanguineous and had no significant family history.

A generalized urticarial-like rash was noted on the first day of life (Figure 2). The infant was admitted to a local neonatal intensive care unit (NICU) due to concerns of early-onset sepsis, particularly given the history of meconium-stained liquor. Initial laboratory investigations revealed significantly elevated inflammatory markers: white blood cell count (WBC) 29.95 × 10⁹/L (reference: 5–21) and C-reactive protein (CRP) 35.06 mg/L (reference: < 3). Despite administration of broad-spectrum antibiotics (Ampicillin 50 mg/kg per dose, q12 h, and Meropenem 20 mg/kg per dose, q12 h, for 7 days) and intravenous methylprednisolone (2 mg/kg/day, for 2 days), the rash persisted, and inflammatory markers remained elevated.

Figure 2

Figure 2. Urticarial-like rash observed at birth: scattered erythematous plaques of variable size, some coalescing into larger patches. Rash was blanchable on pressure and persisted despite empirical treatment. (The arrow points to the rash).

Due to the persistent, unexplained inflammation, the infant was transferred to our tertiary NICU on the 8th day of life for further management. On admission, physical examination was significant for frontal bossing, a widespread, migratory, blanching urticarial rash with areas of confluence, and palpable axillary lymphadenopathy (approximately 1 cm in diameter). Examination of the lower limbs revealed a symmetrical arthropathy involving the knees and ankles, characterized by swelling, and tenderness on passive movement, resulting in reduced spontaneous activity. Recurrent febrile episodes (temperature 38–38.3°C) occurred every 2–6 days, each lasting less than 24 h. The clinical course over the subsequent weeks was characterized by recurrent febrile episodes and fluctuating rash intensity, despite multiple empirical therapies.

A comprehensive diagnostic workup was pursued to elucidate the cause of the refractory inflammation. Lumbar puncture performed on day 9 revealed CSF findings indicative of aseptic meningitis: pleocytosis (105 × 10⁶/L), elevated protein (1.32 g/L), and hypoglycorrhachia (1.68 mmol/L). Cranial MRI on day 14 was unremarkable. Initial automated auditory brainstem response (AABR) showed a “refer” result in the left ear. Critically, extensive microbiological investigations returned negative.

The patient's hospital course was characterized by persistent symptoms despite multiple empirical therapeutic interventions. She was initially treated with a combination of intravenous Ampicillin and Meropenem, which was later adjusted to vancomycin in combination with Meropenem. Additional interventions included antifungal therapy (Fluconazole), intravenous immunoglobulin (IVIG), and a trial of intravenous Methylprednisolone, which provided only transient and incomplete symptom control (see Supplementary Table S2 for detailed timeline).

Given the constellation of findings—early-onset urticarial rash, chronic meningitis, arthropathy, frontal bossing, and persistently elevated inflammatory markers unresponsive to conventional therapies—a strong suspicion for a monogenic autoinflammatory disease, was raised. After obtaining informed consent from the parents, whole-exome sequencing (WES) was performed.

Genetic analysis revealed a heterozygous missense variant (c.2263G>A) in exon 4 of the NLRP3 gene, resulting in an amino acid change from glycine to arginine at position 755 (p.Gly755Arg). Sanger sequencing confirmed the presence of this variant in the proband and its absence in both parents, confirming its de novo origin (Figure 3). This variant was interpreted as pathogenic according to the American College of Medical Genetics and Genomics (ACMG) standards and guidelines (evidence codes: PS2, PS3_MOD, PS4_MOD, PM2_SUP, PP2, PP3), confirming the diagnosis of NOMID.

Figure 3

Figure 3. Genetic findings in the proband and parents: Sanger sequencing confirmed a heterozygous missense mutation in the NLRP3 gene (c.2263G>A, p.Gly755Arg) in the proband. Both parents carried the wild-type all ele, confirming the mutation as de novo.

Targeted therapy with subcutaneous canakinumab was initiated at 48 days of life (2 mg/kg every 8 weeks). The response was rapid, with resolution of rash and fever within 24 h and normalization of inflammatory markers. A transient CRP rise to 10 mg/L before the second dose led to a dose increase to 3 mg/kg every 8 weeks. Thereafter, the patient achieved clinical and serological remission during 13 months of follow-up (Supplementary Table S2).

Monitoring and Outcomes: A standardized protocol was implemented to monitor efficacy, adverse events, and infections. This included:

a. Bi-monthly assessments: Complete blood count, CRP, liver and renal function, BAEP, and fundoscopic examinations (Figure 4).

b. Quarterly assessments: Neurodevelopmental evaluation using the Gesell Developmental Scales (Supplementary Table S3).

c. All monitored parameters remained normal throughout follow-up, confirming sustained remission without treatment-related complications or disease recurrence.

d. Growth: Despite clinical remission, her linear growth and weight gain remained delayed, with both parameters persistently below the 10th percentile.

Figure 4

Figure 4. Longitudinal changes in white blood cell count and C-reactive protein following canakinumab treatment in a case of neonatal-onset multisystem inflammatory disease. The red arrow indicates the time of definitive diagnosis and initiation of canakinumab treatment. The black annotation denotes the canakinumab dosage of 2 mg/(kg·day). During follow-up, a mild elevation in both white blood cell (WBC) count and C-reactive protein (CRP) was observed. After the dosage was adjusted to 3 mg/kg/day, both WBC and CRP decreased to within the normal range.

4 Discussion

We present a seminal case of NOMID in a Chinese neonate, notable for several key aspects: it is the earliest genetically confirmed case in China, it harbors a rare NLRP3 (p.Gly755Arg) mutation, and it demonstrates the profound efficacy of very early intervention with canakinumab, initiated at 48 days of life, in achieving clinical and biochemical remission without emerging serious complications during the 13-month follow-up.

The clinical presentation of our patient is a textbook example of the classic NOMID triad, manifesting with urticarial rash, aseptic meningitis, and joint involvement within the first week of life. The initial presentation of our patient—characterized by neonatal-onset fever, urticarial rash, and elevated inflammatory markers—understandably prompted a broad differential diagnosis. It was crucial to systematically rule out more common entities before arriving at the rare diagnosis of NOMID. First, severe bacterial infections, including neonatal sepsis and meningitis, were primary concerns. However, the persistence of symptoms despite broad-spectrum antibiotic coverage, coupled with consistently negative bacterial cultures (blood and CSF) and normal procalcitonin levels, argued strongly against an ongoing bacterial process. Second, congenital infections (e.g., TORCH syndrome) were considered due to the multi-system involvement. These were effectively excluded by negative serological and PCR testing for relevant pathogens. Third, the urticarial rash and systemic inflammation led to the consideration of neonatal lupus erythematosus. This was ruled out by the absence of maternal anti-Ro/SSA and anti-La/SSB antibodies. Finally, the fulminant systemic inflammatory response and highly elevated ferritin raised the possibility of hemophagocytic lymphohistiocytosis (HLH). Nevertheless, key diagnostic criteria for HLH, such as persistent cytopenias, significant hypofibrinogenemia, and markedly elevated soluble CD25 levels, were absent. The constellation of sterile meningitis, characteristic bony involvement (frontal bossing), and a steroid-refractory, relapsing-remitting course ultimately pointed towards a monogenic autoinflammatory disease, guiding the decision to pursue genetic testing which confirmed NOMID. The clinical management pathway for neonates with persistent urticaria and systemic inflammation is summarized in the flowchart in Figure 5.

Figure 5

Figure 5. Diagnostic and management pathway for neonates with persistent Urticaria and systemic inflammation.

Our systematic review of 52 Chinese NOMID cases (6–21) provides the most comprehensive characterization of this disease in the Chinese population to date. The clinical manifestations were largely consistent with those reported in other international cohorts (5, 28) (Supplementary Table S4), with fever (96.6%) and skin rash (100%) being the most common features, followed by frequent central nervous system involvement (86.6%) and musculoskeletal abnormalities (82.1%). However, the prevalences of hearing impairment, ocular involvement, and renal amyloidosis in our cohort were lower than those in the Japanese cohort. This discrepancy may be attributed to the retrospective nature of our study, which is susceptible to under-reporting bias, combined with the relatively short follow-up duration, potentially leading to an underestimation of long-term sequelae accumulation. In contrast, when compared to the mixed international CAPS cohort, both the Chinese and Japanese NOMID cohorts exhibited a higher overall burden of complications, further validating NOMID as the most severe phenotypic subtype within the CAPS spectrum.

Our patient exhibited significant growth delay (length and weight below the 10th percentile) at the time of diagnosis. This is a well-documented feature in infants with NOMID and is multifactorial in origin (1, 5). The primary driver is believed to be the chronic systemic inflammation itself. The persistent overproduction of IL-1β and other pro-inflammatory cytokines creates a catabolic state, disrupts the growth hormone axis, and suppresses appetite, leading to inadequate nutritional intake (1, 15). Furthermore, joint involvement and arthropathy can contribute to discomfort and functional limitations, potentially exacerbating feeding difficulties and reducing physical activity, which may indirectly impact growth (5). While the contribution of chronic inflammation and nutritional status is paramount, a direct inhibitory effect of cytokines on chondrocyte function and bone growth plates is also postulated (1). The observed catch-up growth following the initiation of canakinumab, which led to rapid inflammatory control, strongly supports the central role of IL-1β-driven inflammation as the underlying cause rather than the treatment itself. This aligns with long-term follow-up studies of canakinumab-treated CAPS patients, which have not identified a significant adverse effect on growth; conversely, therapy often allows for the amelioration of pre-existing growth failure (27, 28).

The p.Gly755Arg variant identified in our patient is located within the leucine-rich repeat (LRR) domain of the NLRP3 protein. This domain is involved in protein-protein interactions and autoinhibition. Mutations in this region are mechanistically intriguing; recent evidence suggests they can promote NLRP3 hyperactivation through multiple mechanisms, including destabilizing autoinhibition, enhancing NEK7-driven inflammasome assembly, and impairing regulatory ubiquitination, leading to protein accumulation (31). Recent high-resolution cryo-EM structural studies—including the visualization of the active NLRP3 inflammasome disc, the inhibited NLRP3 decamer, and the full-length NLRP3 “cage”—have definitively established that the LRR domain plays a central role in regulating NLRP3 activation by maintaining an autoinhibited conformation (3, 32, 33). These structural models posit that pathogenic mutations within the LRR domain, such as p.Gly755Arg, likely lead to the release of this autoinhibited state by disrupting critical intramolecular interfaces, thereby resulting in spontaneous NLRP3 activation (3, 32, 33). This mechanism, grounded in structural biological findings, provides a powerful explanation for the severe, neonatal-onset NOMID phenotype observed in our case. Clinically, variants in the LRR domain have been associated with a severe phenotype and a reportedly higher incidence of sensorineural hearing loss (31). The fact that our patient's hearing normalized completely after treatment is therefore a powerful testament to the remarkable efficacy of preemptive IL-1 blockade in preventing this devastating complication. To date, only five other cases with this specific variant have been reported globally (4, 22, 23, 34, 35) all of whom presented with the severe classic NOMID phenotype, reinforcing its pathogenicity.

It is crucial to note that approximately one-third of patients with a classic clinical phenotype of NOMID do not have an identifiable germline mutation on standard Sanger sequencing (22, 23). This is often due to somatic NLRP3 mosaicism, which requires next-generation sequencing techniques on DNA from affected tissues (e.g., skin, blood subpopulations) or highly sensitive blood tests for detection. Therefore, a negative genetic test should not definitively rule out the diagnosis in a highly suggestive clinical context, and further specialized testing should be pursued.

The management of NOMID/CINCA syndrome has been revolutionized by IL-1 inhibitors, including anakinra and canakinumab (1). For the most severe phenotype of NOMID, potent IL-1 blockade with either anakinra or canakinumab is required (1, 29).

Anakinra demonstrates rapid efficacy, with landmark studies confirming its ability to control systemic inflammation and ameliorate neurological manifestations (24). Its sustained effectiveness and safety profile have been further established through long-term follow-up studies (25). However, its requirement for daily subcutaneous injections (1–2 mg/kg/day) can present challenges for long-term adherence, particularly in pediatric patients (1, 24, 25).

In contrast, canakinumab offers superior dosing convenience due to its prolonged half-life, allowing for subcutaneous administration every 8 weeks (2–4 mg/kg, with a maximum of 150 mg for children weighing 7–40 kg) (26). Large-scale, real-world studies and registry data have consistently validated its exceptional efficacy in achieving and maintaining complete disease remission, while significantly improving treatment adherence and quality of life (27, 28).

For our case, canakinumab was selected based on drug availability and long-term adherence considerations. Treatment achieved remarkable outcomes: rapid normalization of inflammatory markers, complete rash resolution, normalized CSF cell counts, and significant hearing improvement. The choice of canakinumab was also supported by emerging evidence of its favorable safety profile and dosing convenience in very young infants. This case of early-onset NOMID confirms canakinumab's excellent efficacy and safety in very young patients, providing valuable guidance for clinical decision-making in similar scenarios.

However, it is important to note that the follow-up period of 13 months, while demonstrating excellent initial response, is relatively short. Long-term complications of NOMID, including hearing loss, visual impairment, and amyloidosis, may develop later in life. Therefore, continuous long-term monitoring of our patient is essential to fully assess the sustained efficacy and safety of canakinumab therapy.

The objective longitudinal data presented in our case underscore several key points. First, the rapid normalization of CRP and WBC following canakinumab initiation (Figure 4) provides serological confirmation of the drug's efficacy in suppressing NLRP3-mediated inflammation. Second, the normalization of BAEP findings and the absence of ocular pathology demonstrate the critical role of early IL-1β blockade in preventing irreversible organ damage, particularly to the nervous system. Finally, the formal developmental assessment confirming age-appropriate milestones strengthens the evidence that controlling neuroinflammation from early infancy can preserve neurodevelopmental potential.

Diagnosing NOMID in the neonatal period remains challenging due to the absence of formal, validated criteria for this age group. In the present case, the diagnosis was established by integrating proposed clinical features from established classification systems such as the Eurofever/PRINTO criteria (36), the presence of the classic triad (urticarial rash, aseptic meningitis, and arthropathy), rigorous exclusion of alternative diagnoses, and definitive genetic confirmation of a pathogenic NLRP3 mutation (37). This case report, along with other real-world evidence (38), underscores the urgent need to develop more sensitive and standardized diagnostic algorithms for early infancy, as prompt recognition is critical to prevent life-long sequelae.

5 Study limitations

This study has several limitations that should be considered. First, its retrospective design, reliant on previously published case reports, may be subject to publication and selection biases. Second, the 13-month follow-up period, while demonstrating excellent initial outcomes, is relatively short for a chronic lifelong disease like NOMID. The risk of long-term sequelae, such as hearing loss, amyloidosis, or visual impairment, persists. Consequently, continuous, long-term monitoring of organ development, neurocognitive function, and potential adverse effects of biologic therapy is essential to fully ascertain the sustained efficacy and safety of canakinumab in this patient.

6 Conclusion

This case and the accompanying literature review deliver several critical messages for clinicians, particularly neonatologists and pediatric intensivists:

1. NOMID can present on the first day of life. A persistent urticarial rash in a neonate should never be dismissed and should immediately prompt consideration of autoinflammatory etologies.

2. The diagnostic delay in China is unacceptably long. Closing this gap requires increased awareness and a lower threshold for genetic testing in neonates with unexplained inflammation.

3. Genotype-Phenotype Correlations exist but should not deter testing. Even rare variants in domains like LRR can cause severe disease.

4. Early treatment is paramount. The excellent outcome in our patient, compared to the significant morbidity in historically delayed cases, provides compelling evidence that prompt genetic diagnosis and immediate initiation of IL-1 blockade can fundamentally alter the natural history of NOMID, preventing lifelong disability and ensuring normal development. Canakinumab is effective and safe even in early infancy.

5. Somatic Mosaicism is a key consideration in mutation-negative patients with a classic phenotype.

In conclusion, this report underscores NOMID as a devastating but treatable cause of neonatal systemic inflammation. Vigilance, early genetic testing, and swift targeted therapy are the keys to transforming outcomes for these children.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/snp/, rs1305028279.

Ethics statement

The studies involving humans were approved by the Ethics Committee of Wuhan Children's Hospital affiliated with Tongji Medical College, Huazhong University of Science and Technology (No.2025R085-E01). Written informed consent for participation and publication was obtained from the patient's parents. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants' legal guardians/next of kin. Written informed consent was obtained from the individual(s), and minor(s)' legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Author contributions

LZh: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Writing – original draft, Writing – review & editing, Data curation. LZe: Conceptualization, Formal analysis, Methodology, Resources, Software, Supervision, Visualization, Writing – original draft, Writing – review & editing. WY: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Writing – original draft, Writing – review & editing, Supervision, Validation, Visualization.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Scientific Research Project of Wuhan Children’s Hospital (Grant No. 2022FE002).

Acknowledgments

We thank the patient's family for their cooperation.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Correction Note

A correction has been made to this article. Details can be found at: 10.3389/fped.2026.1787121.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2025.1702819/full#supplementary-material

Supplementary Table 1 | Clinical characteristics of 52 neonatal cases with NOMID reported in China.

Supplementary Table 2 | Timeline of Clinical Presentation, Diagnostic Workup, Treatment, and Response.

Supplementary Table 3 | Developmental Assessment Using the Gesell Developmental Schedules During Follow-up.

Supplementary Table 4 | Comparative Analysis of Demographic, and Clinical Features among Chinese NOMID Cohort, International CAPS Cohort, and Japanese NOMID Cohort.

References

1. Finetti M, Omenetti A, Federici S, Caorsi R, Gattorno M. Chronic infantile neurologic, cutaneous, and articular (CINCA) syndrome: a review. Orphanet J Rare Dis. (2016) 11(1):167. doi: 10.1186/s13023-016-0542-8

PubMed Abstract | Crossref Full Text | Google Scholar

2. Stojanov S, Weiss M, Lohse P, Belohradsky BH. A novel CIAS1 mutation and plasma/cerebrospinal fluid cytokine profile in a German patient with neonatal-onset multisystem inflammatory disease responsive to methotrexate therapy. Pediatrics. (2004) 114(1):e124–7. doi: 10.1542/peds.114.1.e124

PubMed Abstract | Crossref Full Text | Google Scholar

3. Andreeva L, David L, Rawson S, Shen C, Pasricha T, Pelegrin P, et al. NLRP3 Cages revealed by full-length mouse NLRP3 structure control pathway activation. Cell. (2021) 184(26):6299–6312.e22. doi: 10.1016/j.cell.2021.11.011

PubMed Abstract | Crossref Full Text | Google Scholar

4. Matsubayashi T, Sugiura H, Arai T, Oh-Ishi T, Inamo Y. Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. Acta Paediatr. (2006) 95(2):246–9. doi: 10.1080/08035250500341451

PubMed Abstract | Crossref Full Text | Google Scholar

5. Levy R, Gérard L, Kuemmerle-Deschner J, Lachmann HJ, Koné-Paut I, Cantarini L, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the eurofever registry. Ann Rheum Dis. (2015) 74(11):2043–9. doi: 10.1136/annrheumdis-2013-204991

PubMed Abstract | Crossref Full Text | Google Scholar

6. Guan N, Li B, Wu Y. Report of a child with neonatal-onset multisystem inflammatory disease and review of the literature. Zhonghua Er Ke Za Zhi. (2014) 52(12):932–6. doi: 10.3760/cma.j.issn.0578-1310.2014.12.012

PubMed Abstract | Crossref Full Text | Google Scholar

7. Fu Q, Chen J, Tacu C, Chen S. A platform setup for genetic diagnosis of cryopyrin-associated periodic syndrome and a case report. Chin J Rheumatol. (2014) 18(1):29–33. doi: 10.3760/cma.j.issn.1007-7480.2014.01.007

Crossref Full Text | Google Scholar

8. Zhao PW, Ding Y, Yin W, Yue X, He XL. Cryopyrin-associated periodic syndrome: one case report. J Clin Pediatr. (2015) 33(6):579–82. doi: 10.3969/j.issn.1000-3606.2015.06.020

Crossref Full Text | Google Scholar

9. Zhang J, Li C, Tan X, Piao Y, Han T, Kuang W, et al. Analyses of gene mutation, clinical phenotype, treatment and follow-up of 10 CINCA cases. Chin J Rheumatol. (2019) 23(8):536–9. doi: 10.3760/cma.j.issn.1007-7480.2019.08.007

Crossref Full Text | Google Scholar

10. Luo XY, Chen AW, Cai JH, Fang J, Wang H. TNF-α blockade ameliorates inflammation in two children with CINCA syndrome. J Dermatol. (2020) 47(8):903–6. doi: 10.1111/1346-8138.15414

PubMed Abstract | Crossref Full Text | Google Scholar

11. Jiang WJ, Man J, Qian XW, Wang HS, Wang P, Zhai XW. Umbilical cord blood stem cell transplantation for CINCA syndrome and literature review. Fudan Univ J Med Sci. (2021) 48(3):349–55. doi: 10.3969/j.issn.1672-8467.2021.03.011

Crossref Full Text | Google Scholar

12. Zhou Y, Wang W, Zhong L, Wang L, Ma M, Tang X, et al. Clinical and genetic spectrum of 14 cases of NLRP3-associated autoinflammatory disease in China. Orphanet J Rare Dis. (2022) 17(1):214. doi: 10.1186/s13023-022-02364-z

PubMed Abstract | Crossref Full Text | Google Scholar

13. An Y, Chen L, Huang WD, Zhao JG, Wei JK, Wang Z, et al. Neonatal-onset multisystem inflammatory disease: a case report and literature review. Chin Pediatr Emerg Med. (2023) 30(3):229–33. doi: 10.3760/cma.j.issn.1673-4912.2023.03.015

Crossref Full Text | Google Scholar

14. Xie M, Wan J, Zheng X, Zou X, Chen W, Zhang K, et al. A de novo NLRP3 variant resulting in autoinflammatory disease in a Chinese newborn: case report. Front Immunol. (2023) 14:1238551. doi: 10.3389/fimmu.2023.1238551

PubMed Abstract | Crossref Full Text | Google Scholar

15. Zhao C, Liu C, Li X. Clinical characteristics of Chinese neonates with NOMID: a case report and literature review. Front Immunol. (2024) 14:1291345. doi: 10.3389/fimmu.2023.1291345

PubMed Abstract | Crossref Full Text | Google Scholar

16. Shangguan Y, Ding X, Ma L, Cai YX, Xiang S, Huang XF, et al. Clinical and genetic spectrum of nine cases of NLRP3-associated autoinflammatory disease and identification of a novel NLRP3 mutation. J Immunol Res. (2024) 2024:5722548. doi: 10.1155/2024/5722548

PubMed Abstract | Crossref Full Text | Google Scholar

17. Zhang C, Yu Z, Gao S, Ma M, Gou L, Wang C, et al. Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study. Pediatr Rheumatol Online J. (2023) 21(1):124. doi: 10.1186/s12969-023-00881-0

PubMed Abstract | Crossref Full Text | Google Scholar

18. Shu Z, Zhang Y, Han T, Li Y, Piao Y, Sun F, et al. The genetic and clinical characteristics and effects of canakinumab on cryopyrin-associated periodic syndrome: a large pediatric cohort study from China. Front Immunol. (2023) 14:1267933. doi: 10.3389/fimmu.2023.1267933

PubMed Abstract | Crossref Full Text | Google Scholar

19. Zhu X, Fan J, Huang Y, Xu Y, Yang Z, Weng R, et al. Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China. Pediatr Rheumatol Online J. (2024) 22(1):87. doi: 10.1186/s12969-024-01023-w

PubMed Abstract | Crossref Full Text | Google Scholar

20. Ma L, Tian F, Li CJ, Yang LL, Yang ZC. Genetic analysis of a child with chronic infantile neurological cutaneous articular syndrome and short stature and literature review. In J Genet. (2024) 47(4):317–24. doi: 10.3760/cma.j.cn231536-20240118-00011

Crossref Full Text | Google Scholar

21. Ruan Y, Ge T, Wang Y, Zhang T, Song F. Case report: a heterozygous mutation of NLRP3 in a Chinese child with NLRP3-AID. Front Pediatr. (2025) 13:1411603. doi: 10.3389/fped.2025.1411603

PubMed Abstract | Crossref Full Text | Google Scholar

22. Tanaka N, Izawa K, Saito MK, Sakuma M, Oshima K, Ohara O, et al. High incidence of NLRP3 somatic mosaicism in CINCA patients: an international multicenter study. Arthritis Rheum. (2011) 63(11):3625–32. doi: 10.1002/art.30512

PubMed Abstract | Crossref Full Text | Google Scholar

23. Saito M, Nishikomori R, Kambe N, Fujisawa A, Tanizaki H, Takeichi K, et al. Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in CAPS. Blood. (2008) 111(4):2132–41. doi: 10.1182/blood-2007-06-094201

PubMed Abstract | Crossref Full Text | Google Scholar

24. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. (2006) 355(6):581–92. doi: 10.1056/NEJMoa055137

PubMed Abstract | Crossref Full Text | Google Scholar

25. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. (2010) 62(1):258–67. doi: 10.1002/art.25057

PubMed Abstract | Crossref Full Text | Google Scholar

26. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, et al. Two-year results of canakinumab in CAPS: an open-label, multicenter phase III study. Ann Rheum Dis. (2011) 70(12):2095–102. doi: 10.1136/ard.2011.152728

PubMed Abstract | Crossref Full Text | Google Scholar

27. Brogan PA, Hofer M, Kuemmerle-Deschner JB, Koné-Paut I, Roesler J, Kallinich T, et al. Long-term efficacy and safety of canakinumab in CAPS patients aged ≤5 years. Arthritis Rheumatol. (2019) 71(11):1955–63. doi: 10.1002/art.41004

PubMed Abstract | Crossref Full Text | Google Scholar

28. Miyamoto T, Izawa K, Masui S, Yamazaki A, Yamasaki Y, Matsubayashi T, et al. Clinical characteristics of cryopyrin-associated periodic syndrome and long-term real-world efficacy and tolerability of canakinumab in Japan: results of a nationwide survey. Arthritis Rheumatol. (2024) 76(6):949–62. doi: 10.1002/art.42808

PubMed Abstract | Crossref Full Text | Google Scholar

29. Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron K, et al. 2021 EULAR/ACR points to consider for IL-1 mediated autoinflammatory diseases. Arthritis Rheumatol. (2022) 74(7):1102–11. doi: 10.1002/art.42139

PubMed Abstract | Crossref Full Text | Google Scholar

30. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. (2021) 372:n71. doi: 10.1136/bmj.n71

PubMed Abstract | Crossref Full Text | Google Scholar

31. Cescato M, Zhu YYJ, Le Corre L, Py BF, Georgin-Lavialle S, Rodero MP. Implication of the LRR domain in NLRP3 inflammasome regulation. Cells. (2024) 13(16):1365. doi: 10.3390/cells13161365

PubMed Abstract | Crossref Full Text | Google Scholar

32. Xiao L, Magupalli VG, Wu H. Cryo-EM structures of the active NLRP3 inflammasome disc. Nature. (2023) 613(7944):595–600. doi: 10.1038/s41586-022-05570-8

PubMed Abstract | Crossref Full Text | Google Scholar

33. Hochheiser IV, Pilsl M, Hagelueken G, Moecking J, Marleaux M, Brinkschulte R, et al. Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature. (2022) 604(7904):184–9. doi: 10.1038/s41586-022-04467-w

PubMed Abstract | Crossref Full Text | Google Scholar

34. Jesus AA, Silva CA, Segundo GR, Aksentijevich I, Fujihira E, Watanabe M, et al. Phenotype-genotype analysis of cryopyrin-associated periodic syndromes: description of a rare non-exon 3 and a novel CIAS1 missense mutation. J Clin Immunol. (2008) 28(2):134–8. doi: 10.1007/s10875-007-9150-7

PubMed Abstract | Crossref Full Text | Google Scholar

35. Watanabe M, Nishikomori R, Fujimaki Y, Heike T, Ohara A, Saji T. Live-attenuated vaccines in a CAPS patient receiving canakinumab during infancy. Clin Case Rep. (2017) 5(11):1750–5. doi: 10.1002/ccr3.1149

PubMed Abstract | Crossref Full Text | Google Scholar

36. Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, et al. Eurofever registry and the paediatric rheumatology international trials organisation (PRINTO). classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. (2019) 78(8):1025–32. doi: 10.1136/annrheumdis-2019-215048

PubMed Abstract | Crossref Full Text | Google Scholar

37. Bonet N, Mascaro JM Jr, Hurtado-Navarro L, Angosto-Bazarra D, Callejas-Rubio JL, Clemente D, et al. Novel insights into the clinical features, genetic Spectrum and clonal evolution of patients carrying NLRP3 mosaicism. J Clin Immunol. (2025) 45(1):134. doi: 10.1007/s10875-025-01922-x

PubMed Abstract | Crossref Full Text | Google Scholar

38. Çağlayan Ş, Mardinoğlu G, Yarar MH, Ulu K, Coşkuner T, Yiğit RE, et al. The assessment of autoinflammatory disease classification criteria (eurofever/PRINTO) in a real-life cohort. Clin Rheumatol. (2023) 42(6):1645–53. doi: 10.1007/s10067-023-06557-0

PubMed Abstract | Crossref Full Text | Google Scholar